BUZZ - Personalis stock drops as BTIG lowers rating and expects no bidding for Tempus deal
路透社2026/10/06 14:31October 6 – Personalis (PSNL.O) shares fell about 2% to $16.12. BTIG downgraded the cancer screening company from “Buy” to “Neutral.” The brokerage stated that Tempus AI TEM.O will complete its acquisition of PSNL in the coming months; and believes that “despite an ongoing bidding process,” no higher offer will emerge. Tempus AI has agreed to acquire Personalis by July 2026 (link), with a deal valued at approximately $1.5 billions. Out of five brokerages, one has assigned a “Strong Buy” rating to the stock, while four have rated it “Hold,” with a median price target of $16.25—data compiled by LSEG. Including today’s gains, the stock has risen a cumulative 104.40% so far this year. (To facilitate non-English speakers, Reuters has automated this report into several other languages. Because automated translation may contain errors or lack the desired context, Reuters does not guarantee the accuracy of such translations and provides them solely for the reader’s convenience. Reuters assumes no liability for any damage or loss arising from the use of automated translation.)
October 6 - ** Personalis (PSNL.O) shares fell about 2% to $16.12
** BTIG downgraded the cancer testing company from "Buy" to "Neutral"
** The brokerage said Tempus AI TEM.O will complete the acquisition of PSNL in the coming months; it believes that "despite the bidding process," there will be no higher offer
** Tempus AI has agreed to acquire Personalis (link) in July 2026, with the deal valued at about $1.5 billion
** Of five analysts, one rates the stock as "Strong Buy" and four rate it as "Hold," with a median price target of $16.25—data compiled by LSEG
** Including today's gain, the stock has risen a cumulative 104.40% so far this year
(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of translated texts and provides them for readers’ convenience only. Reuters accepts no responsibility for any losses or damages arising from the use of automated translation functions.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Dollar Index slips from its 18-month high
Monnalisa shares delist from Euronext Growth Milan
Monnalisa’s delisting from trading on Euronext Growth Milan took effect today. The company is preparing a shareholder buyback process led by Modamet and Jafin Due for investors seeking to sell. Further details are due in coming days on the purchase window and a single settlement date for the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monnalisa S.p.A. published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
AI agent security risks raise concerns; JPMorgan CEO Dimon: Anthropic's Mythos may amplify cyber threats by about 10 times
JPMorgan CEO Jamie Dimon stated in an interview that Mythos AI, a model under Anthropic, could increase global cybersecurity risks by approximately 10 times.
Updated version 3 - Becton Dickinson commits to invest 19 billion dollars in an agreement with the government.
BD will invest $3 billion to expand its manufacturing operations in the United States, aiming to increase the proportion of critical medical supplies sourced domestically to approximately 80%. The agreement links the company’s U.S. manufacturing commitments to tariff relief. Information about the stock price was added in the third paragraph, analyst commentary in the sixth paragraph, and background information in the eleventh paragraph. Siddhi Mahatole, Reuters, October 6 — Becton Dickinson and Company (BDX.N) has become the first major U.S. medical device manufacturer to sign an agreement with the U.S. government to expand domestic manufacturing, with a pledge to invest $19 billion in the coming years in exchange for protection against future tariffs. Under the agreement, the company said on Tuesday it plans to make capital, operational, and supply chain investments in the U.S., with $3 billion specifically allocated to strategic manufacturing facilities across the country. Shares of the medical device maker rose 2.4% in early trading. This deal is one of several measures by the Trump administration to encourage domestic healthcare manufacturing through the threat of tariffs, with several major pharmaceutical companies having already committed billions of dollars toward building and expanding production and R&D facilities in the U.S. The agreement ties BD’s U.S. manufacturing commitments to future exemptions from tariffs on related products and raw materials under Section 232, depending on the final scope of the measures and whether the company achieves agreed-upon milestones. Jefferies analyst Matthew Taylor commented, “We believe clarity on tariff policy, or tariff impacts being potentially ‘not as bad as feared,’ could be an inflection point for the medtech sector.” He added, “We are curious if there are more medtech-related announcements pending.” The company plans to increase annual U.S. production by around 5 billion basic medical supply units, raising the domestic supply share to roughly 80%. BD also intends to use U.S.-made steel to manufacture all needles for the U.S. market domestically. Becton Dickinson stated that, as the final tariff rates, product range, and implementation timelines remain undetermined, the financial impact of the agreement has not been quantified yet. This announcement builds on President Donald Trump’s Monday statement that the company has agreed to invest $3 billion to shift basic medical product manufacturing to the U.S., with more than $1 billion allocated to Nebraska. In January this year, Becton Dickinson announced a $110 million investment to expand the production of prefilled syringes and needles in Columbus, Nebraska, expected to create about 120 jobs. Syringe products are expected to start shipping to customers by mid-2026.
Crypto prices
More
